A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease

Trial Profile

A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Flurpiridaz F 18 (Primary)
  • Indications Coronary artery disease
  • Focus Diagnostic use
  • Sponsors GE Healthcare
  • Most Recent Events

    • 21 Nov 2017 Status changed from planning to not yet recruiting.
    • 06 May 2015 New trial record
    • 04 May 2015 The US FDA has granted a Special Protocol Assessment in connection with this new second phase III study, according to a according to a Lantheus Medical Imaging media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top